Targeting complex interactions in diverse clinical ecosystems
Our discovery engine has led to impactful therapies that change disease progression across several clinical modalities:
In commercial development
Pulmonary disease
Synedgen’s pulmonary platform, is now out-licensed to Synspira Inc. (Framingham, MA), and the lead asset is currently in Phase 2 clinical trials.
Wound care
Synedgen’s wound care products, SynePure™ Wound Rinse and Catasyn™ Advanced Technology Wound Hydrogel, are currently in commercialization stages and will soon be available for purchase in the U.S. through our partners.
GI mucositis
Synedgen’s therapies provide relief from gastrointestinal side effects of cancer radiation therapy and are in early stages of product development.
In research and development
Sinus health
Synedgen has recently completed pilot clinical trials for its sinus health product. This portfolio is being developed for acute and chronic rhinosinusitis.
Ophthalmic health
Synedgen has been awarded a 3 year grant from the National Eye Institute (NEI) of the National Institutes of Health (NIH) to develop molecules intended to counteract severe, ulcerative eye injury.
